Peter Thiel’s Steroid Olympics Startup Pushes Sketchy Peptides

Peter Thiel-backed Enhanced Games is no longer just selling a drug-permissive sports event. It is also selling consumer performance products and using the same brand to market “LONGER+” and “STRONGER+,” two formulas priced at $119 on its shop as of March 18, 2026, while outside coverage in February 2026 reported the company was already pitching testosterone therapies, peptides, and enhancement protocols to consumers. That matters because peptide marketing sits in a gray, heavily scrutinized corner of U.S. health regulation, where the Food and Drug Administration has repeatedly warned that unapproved or misbranded peptide products can pose real safety risks.

The result is a business model that looks bigger than a one-day meet in Las Vegas. Enhanced’s own site presents the Games as a gateway to a broader “consumer products division,” with a main homepage linking directly to a shop and a science page that frames performance enhancement as medically supervised. The company says the first Enhanced Games are planned for Las Vegas in May 2026, and Associated Press reporting from September 2025 said organizers were offering $500,000 first prizes and a potential $7.5 million purse for a single day of competition.

Enhanced’s March 2026 pitch is no longer only about sport

Enhanced’s public-facing pitch now has three connected parts: the event, the science narrative, and the product funnel. On the company homepage viewed March 18, 2026, visitors see links for “Games,” “Science,” and “Products,” plus a direct “Get Enhanced” path to the store. The homepage also describes “science-backed protocols” and “personalized wellness products and pathways built for you,” language that places consumer health products alongside the sports brand rather than in a separate, distant business line.

The store itself is live. On March 18, 2026, Enhanced’s shop listed LONGER+ at a sale price of $119, down from $200, and STRONGER+ at the same $119 sale price, also marked 41% off. LONGER+ is described as “a longevity formula designed to support healthy aging and cellular function,” while STRONGER+ is described as “a performance formula designed to support strength, power, and recovery.” The site says both are “third-party tested,” “non-GMO,” and “free of unnecessary fillers,” and it adds the standard disclaimer that the statements “have not been evaluated by the Food and Drug Administration.”

That is not the same thing as a peptide storefront in the narrow sense of selling vials labeled for injection. But the broader concern around the company’s direction comes from how the brand is being positioned. UnHerd reported in February 2026 that Enhanced was “already selling testosterone therapies, peptides, and enhancement protocols on its website,” and described the consumer-products business as central to the company’s economics, including plans to go public at a $1.2 billion enterprise value. Because that report is external rather than an official filing, the valuation claim should be treated as reported, not confirmed here. The more durable fact is that Enhanced’s own website now clearly ties its sports brand to direct-to-consumer performance and longevity products.

The May 2026 Las Vegas event is the marketing engine

The sports event remains the attention magnet. Enhanced’s seed-funding announcement says the company was founded in 2023 by Aron D’Souza and describes a model in which athletes are paid and can win million-dollar bonuses for world records. AP reported in September 2025 that the company had signed five athletes for a Las Vegas event scheduled for May 2026 featuring track, swimming, and weightlifting, with $500,000 first prizes. A separate AP report from July 2025 said organizers promised $1 million bonuses for world-record performances.

That matters because the event is not just a competition; it is a proof-of-concept for a commercial thesis. Enhanced’s homepage says the company is building “the future of human performance,” and its science page says it advocates “safe, responsible, and clinically supervised use of performance enhancements.” UnHerd’s February 2026 report made the commercial logic explicit, saying the Games were the “kickoff to a consumer products division” and that clinical data generated by athletes could support future product development. Even if that clinical-data ambition never reaches FDA approval, the branding strategy is already visible: elite athletes, controversial enhancement, then consumer wellness products sold under the same banner.

The company has also tried to build legitimacy through personnel. Enhanced’s science page lists an Independent Medical Commission and an Independent Scientific Commission, including Prof. Guido Pieles, Dr. Michael Sagner, Dr. Leo Nissola, Prof. George Church, and Prof. Jose Antonio, among others, as of March 18, 2026. Those names show the company understands the reputational problem and is trying to answer it with credentialed advisors. But advisory boards do not change the underlying regulatory status of products sold to consumers in the U.S.

Why peptides trigger more scrutiny than the marketing suggests

The word “peptide” covers a wide range of substances, from approved medicines to research chemicals to ingredients marketed in supplements. That breadth is exactly why the category gets messy. The FDA’s consumer guidance says dietary supplements are regulated under the food framework, not as pre-approved drugs, and it also notes that ingredients approved as new drugs, licensed as biologics, or authorized for investigation under an IND are generally excluded from the dietary supplement definition unless they were previously marketed as food or supplements.

That distinction is central. Some peptides are legitimate prescription drugs. Others are sold online with “research use only” labels while being marketed in ways that imply human use. In a February 26, 2025 warning letter to USApeptide.com, the FDA said that despite disclaimers such as “research use only” and “not for human consumption,” evidence from the website showed certain products were intended for human use, making them unapproved and misbranded drugs in the agency’s view. The FDA said it sent that warning letter because of “inherent risks to consumers” who purchase such products.

The agency has also issued broader warnings around compounded GLP-1 drugs, a peptide-adjacent category that exploded during shortages. FDA guidance updated in recent months says compounded drugs are not FDA-approved and notes adverse-event reports tied to compounded semaglutide and tirzepatide, including dosing concerns. The FDA also warned in 2023 against using compounded drugs from Fullerton Wellness because of sterility concerns involving sterile products including semaglutide and tirzepatide injections.

Those examples do not prove that every peptide product is unsafe or unlawful. They do show why a startup built around enhancement, testosterone, and peptides will face skepticism when it tries to sell directly to consumers. In this market, the gap between “science-backed” branding and FDA-cleared evidence is often wide.

Anti-doping rules make the peptide issue even sharper

Enhanced’s entire premise is that athletes should be allowed to use substances banned in conventional sport. That includes peptide hormones and related compounds. USADA’s 2026 WADA Prohibited List materials state that the list identifies substances and methods prohibited in and out of competition, and the 2026 update specifically highlights “Peptide Hormones, Growth Factors, and Related Substances” among the categories athletes need to understand. WADA’s 2026 list took effect on January 1, 2026.

USADA also says a substance can be considered for prohibition if it meets two of three criteria: it has the potential to enhance performance, it represents an actual or potential health risk to the athlete, or it violates the spirit of sport. That framework is almost a direct rebuttal to Enhanced’s branding. The company argues that medically supervised enhancement can be safe and transparent; anti-doping authorities argue that many of the same substances are prohibited precisely because they combine performance effects with health risk.

The conflict is not abstract. In July 2025, WADA president Witold Banka said the agency would urge U.S. authorities to find legal ways to block the Las Vegas event, according to AP. That same report said organizers were encouraging athletes to use performance-enhancing drugs under medical supervision. So when Enhanced moves from a sports provocation to a consumer-products business, it carries the baggage of a model that the world’s anti-doping authorities are actively trying to stop.

The business logic is clear even if the medical case is not

The strongest case for Enhanced is commercial, not scientific. Traditional Olympic and sub-elite athletes are often underpaid. AP reported that Enhanced’s lawsuit contrasted World Aquatics’ $7.1 million in 2024 prize money spread across 319 swimmers with Enhanced’s claimed potential $7.5 million purse for a single day in 2026. That is a simple recruiting pitch: more money, fewer restrictions, more spectacle.

The consumer-products angle extends that pitch to the public. Enhanced’s shop uses language around aging, vitality, endurance, recovery, and performance, and it features athlete testimonials from Fred Kerley, Megan Romano, and Ben Proud on the storefront viewed March 18, 2026. That is a familiar wellness-commerce formula: elite validation, broad claims, recurring subscriptions, and a disclaimer at the bottom.

The weak point is evidence hierarchy. The store says results referenced are based on “published peer-reviewed studies of individual ingredients at clinical doses,” not on FDA evaluation of the finished products. That is a common distinction in supplements, but it is also where many consumers get misled. Evidence on ingredients is not the same as evidence on the branded stack being sold, in the dose, combination, and population implied by the marketing.

March 18, 2026: what is verified, what is not, and what to watch

Here is what is verified as of Wednesday, March 18, 2026. Enhanced’s official site links its Games brand to a live consumer shop. That shop sells LONGER+ and STRONGER+ for $119 each at sale pricing and markets them for longevity, strength, power, recovery, and cellular function. The company’s science page says it supports clinically supervised enhancement and lists named medical and scientific advisors. The first Enhanced Games are planned for Las Vegas in May 2026, and AP has reported prize figures ranging from $500,000 first prizes to $1 million bonuses for world records.

Here is what is less settled. External reporting says the company is already selling testosterone therapies, peptides, and enhancement protocols, but the live shop page directly accessible on March 18, 2026 prominently shows branded formulas rather than a catalog of injectable peptide drugs. That means the broader “peptides” framing around Enhanced is supported by recent reporting, but the exact current product mix visible to the public may be changing quickly.

What to watch next is straightforward. First, whether Enhanced expands from supplement-style formulas into more explicit peptide or hormone offerings on its official storefront. Second, whether U.S. regulators scrutinize any product claims the way the FDA has scrutinized other peptide sellers and compounded-drug marketers. Third, whether the May 2026 Las Vegas event actually happens on schedule and produces the athlete performances the company needs to keep selling the idea of enhancement as mainstream consumer aspiration.

Conclusion

Enhanced is trying to turn a culture-war sports stunt into a vertically integrated performance brand. The sports event gets attention, the science page supplies legitimacy, and the shop captures consumer demand. That is a coherent business strategy. The problem is that peptides, hormone-adjacent products, and enhancement protocols are not ordinary lifestyle accessories in the eyes of regulators or anti-doping bodies. In the U.S., the FDA has repeatedly warned that unapproved, misbranded, or compounded products in this category can carry sterility, dosing, and labeling risks. So the core issue is not whether Enhanced can market “human potential.” It is whether consumers can clearly tell where evidence ends and branding begins.

Frequently Asked Questions

Q: What is Peter Thiel’s “Steroid Olympics” startup actually selling right now?
A: As of March 18, 2026, Enhanced’s official shop publicly lists two branded products, LONGER+ and STRONGER+, each priced at $119 on sale. The site markets them for healthy aging, cellular function, strength, power, and recovery, and includes an FDA non-evaluation disclaimer.

Q: Is Enhanced Games officially connected to peptide sales?
A: Enhanced’s own homepage links the Games brand directly to its product store, while February 2026 reporting said the company was already selling testosterone therapies, peptides, and enhancement protocols. The live storefront visible on March 18, 2026 prominently shows branded formulas rather than a clear peptide-drug catalog.

Q: Why are people calling the products sketchy?
A: The concern comes from the category, not just the branding. The FDA has warned that some peptide sellers market unapproved and misbranded drugs despite “research use only” disclaimers, and it has also flagged sterility and dosing risks in some compounded injectable products such as semaglutide and tirzepatide.

Q: Are peptides banned in sports?
A: Many are. USADA’s materials for the 2026 WADA Prohibited List identify peptide hormones, growth factors, and related substances as prohibited categories under anti-doping rules. The 2026 list took effect on January 1, 2026, which is one reason Enhanced’s pro-enhancement model clashes so directly with mainstream sport.

Q: When are the first Enhanced Games supposed to happen?
A: The inaugural event is planned for Las Vegas in May 2026. Associated Press reporting said the meet would feature track, swimming, and weightlifting, with $500,000 first prizes and a potential $7.5 million purse, while organizers have also promoted $1 million bonuses for world-record performances.

---

Disclaimer: This article is for informational purposes only and does not constitute financial or investment advice. Cryptocurrency investments carry significant risk, including the possibility of total loss. Always conduct your own research and consult a qualified financial advisor before making investment decisions.